DrugPatentWatch Database Preview

Details for Patent: 9,604,901

« Back to Dashboard

Which drugs does patent 9,604,901 protect, and when does it expire?

Patent 9,604,901 protects REMODULIN, TYVASO, and ORENITRAM, and is included in four NDAs.

This patent has fifteen patent family members in seven countries.

Summary for Patent: 9,604,901

Title:	Process to prepare treprostinil, the active ingredient in Remodulin.RTM.
Abstract:	This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
Inventor(s):	Batra; Hitesh (Herndon, VA), Tuladhar; Sudersan M. (Silver Spring, MD), Penmasta; Raju (Herndon, VA), Walsh; David A. (Palmyra, VA)
Assignee:	United Therapeutics Corporation (Silver Spring, MD)
Application Number:	14/754,932
Patent Claim Types: see list of patent claims	Use; Formulation; Compound;

Drugs Protected by US Patent 9,604,901

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
United Therap	REMODULIN	treprostinil	INJECTABLE;IV (INFUSION), SUBCUTANEOUS	021272-001	May 21, 2002	AP	RX	Yes	Yes				Y
United Therap	REMODULIN	treprostinil	INJECTABLE;IV (INFUSION), SUBCUTANEOUS	021272-002	May 21, 2002	AP	RX	Yes	Yes				Y
United Therap	REMODULIN	treprostinil	INJECTABLE;IV (INFUSION), SUBCUTANEOUS	021272-003	May 21, 2002	AP	RX	Yes	Yes				Y

International Family Members for US Patent 9,604,901

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2710205
China	101903324
China	103274926